Endocannabinoids, metabolic regulation, and the role of diet

Carr, Timothy P.; Jesch, Elliot D.; Brown, Andrew W.

doi:10.1016/j.nutres.2008.08.003

Cited by 27 publications

(21 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has previously been demonstrated that exogenous and endogenous cannabinoids can influence feeding in rodents (Carr et al 2008;Kirkham and Williams 2001). Of particular importance to the current study, it has been shown that ∆ 9 THC can induce overeating even in satiated rats and that these effects are due to exogenous cannabinoid interactions with central eCB systems (Williams et al 1998).…”

Section: Introductionmentioning

confidence: 64%

Cannabis constituents modulate ∆9-tetrahydrocannabinol-induced hyperphagia in rats

et al. 2010

View full text Add to dashboard Cite

All Delta9THC compounds displayed classical Delta9THC effects on feeding, significantly increasing shortterm intake whilst decreasing latency to the first meal. We propose that the subtle adjustment to the meal patterns seen between the purified Delta9THC and Delta9THC-BDS are due to non-Delta9THC cannabinoids present in Delta9THC-BDS. These compounds and other non-cannabinoids have an emerging and diverse pharmacology and can modulate Delta9THC-induced hyperphagia, making them worth further investigation for their therapeutic potential.

show abstract

Section: Introductionmentioning

confidence: 64%

Cannabis constituents modulate ∆9-tetrahydrocannabinol-induced hyperphagia in rats

et al. 2010

View full text Add to dashboard Cite

show abstract

“…CB 1 is strongly expressed in a number of different regions of the central nervous system such as the hypothalamus, hippocampus, and dorsal root ganglia (DRG) where it is known to play a role in modulating appetite (3–5), cognition and memory (6–8), and inflammatory pain, respectively (9). …”

Section: Introductionmentioning

confidence: 99%

Allele-specific Differences in Activity of a Novel Cannabinoid Receptor 1 (CNR1) Gene Intronic Enhancer in Hypothalamus, Dorsal Root Ganglia, and Hippocampus

Nicoll

Davidson

Shanley

et al. 2012

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: Intron 2 of CNR1 gene contains multiple disease-associated SNPs.Results: Allelic variants of a novel enhancer in CNR1 intron 2 affect its MAPK response in hypothalamus and hippocampus.Conclusion: Alleles of enhancer may be functionally linked to obesity and addictive behavior.Significance: Understanding the effects of CNR1 polymorphisms on gene regulation will accelerate understanding of human disease.

show abstract

“…On one hand, it's well known that high-fat diet is an important factor leading to obesity based on the report that ω-6 polyunsaturated fatty acid (precursor of ECs in the body), which can lead to an over-production of ECs, was significantly increased after the intake of high-fat diet [10,11] .…”

Section: Abnormal Levels Of Ecs In Obesitymentioning

confidence: 99%

The endocannabinoid system: A new pharmacological target for obesity treatment?

Zhu

Huang

2009

Neurosci. Bull.

View full text Add to dashboard Cite

Being a great threaten for human health, obesity has become a pandemic chronic disease. There have been several therapeutic treatments for this social health issue, including diet and exercise therapy, medication and surgery, among which the diet is still the most common way. However, none of these therapeutic measures available is ideal, making it necessary to find an effective medical treatment. The endocannabinoid system, which is well known for its contributions in certain mental processes such as relaxation, amelioration of pain and anxiety, and sedation initiation, has been recently reported to play an essential role in regulating appetite and metabolism to maintain energy balance, leading to the belief that endocannabinoid system is closely related to obesity. This new discovery deepens our understanding of obesity, and provides us with a new direction for clinical obesity treatment. Rimonabant is an antagonist for CB1, and has entered the market in some countries. However, although effective as an anti-obesity drug, rimonabant also causes obviously adverse side-effects, thus is being doubted and denied for medical usage.Keywords: obesity; weight loss; endocannabinoids; cannabinoid receptor; cannabinoid CB 1 receptor antagonist; anti-obesity agents; rimonabant As a chronic disease with multi-pathogenesis and a variety of complications, obesity is characterized by excess accumulation of body fat, as measured by "body-mass index" (BMI), for which the body weight of an individual is divided by the square of his height. According to the definition made by World Health Organization (WHO), one whose BMI is within the range of 25-29.9 kg/m 2 is defined as overweight, while within the range of 30.0-39.9 kg/m 2 is defined as obesity, and one whose BMI is 40 kg/m 2 or above is considered as morbid obesity. In the past, overweight and obesity were considered as health concerns only in developed countries. However, with the development of living qualities, more and more people, especially the young, tend to get obesity in both developed and developing countries, and their health is endangered [1,2] . In 1999, obesity was officially documented as a preventable disease by WHO, and it has become the second lethal risk for human life following smoking. Obesity, together with AIDS, drug addiction and alcohol abuse, is considered the four major worldwide medical issues. [3,4] .The current available treatments for obesity include diet and exercise therapy, medication and surgery, and the first one remains the most common. However, it's always easy to lose weight at a moderate level but very hard to keep, as proved by the report that weight loss typically peaks 6 months after treatment; however, by the end of the year, one third of the lost weight has been regained, and usually all the lost weight is regained within 5 years [4,5] . That is, lifestyle intervention seldom works well. Meanwhile, no obesity treatment has been approved by FDA, although a handful of approved medications for illness other than obesity, s...

show abstract

Endocannabinoids, metabolic regulation, and the role of diet

Cited by 27 publications

References 86 publications

Cannabis constituents modulate ∆9-tetrahydrocannabinol-induced hyperphagia in rats

Cannabis constituents modulate ∆9-tetrahydrocannabinol-induced hyperphagia in rats

Allele-specific Differences in Activity of a Novel Cannabinoid Receptor 1 (CNR1) Gene Intronic Enhancer in Hypothalamus, Dorsal Root Ganglia, and Hippocampus

The endocannabinoid system: A new pharmacological target for obesity treatment?

Contact Info

Product

Resources

About